The molecular genetics of haemochromatosis

European Journal of Human Genetics

Volumn 13, Issue 11, 2005, Pages 1172-1185

  Le Gac, Gérald ^a,b   Férec, Claude ^a,b,c  

^a INSERM   (France)

^b Lab National Virologie Biologie Moléculaire l'Etablissement Français Sang   (France)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

Author keywords

Genetic heterogeneity; Haemochromatosis; Iron homeostasis; Onset; Phenotypic heterogeneity

Indexed keywords

FERROPORTIN 1; HEMOJUVELIN; HEPCIDIN; HFE PROTEIN; IRON; TRANSFERRIN RECEPTOR 2;

CELL SURFACE; DISEASE CLASSIFICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; HEMOCHROMATOSIS; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; INHERITANCE; IRON KINETICS; IRON OVERLOAD; IRON TRANSPORT; KNOCKOUT MOUSE; MISSENSE MUTATION; MOLECULAR GENETICS; NONHUMAN; NONSENSE MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; AMINO ACID SEQUENCE; ANIMAL; CLASSIFICATION; GENETICS; GENOTYPE; METABOLISM; MOLECULAR BIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; GENE FREQUENCY; GENOTYPE; HEMOCHROMATOSIS; HUMANS; IRON; MOLECULAR BIOLOGY; MOLECULAR SEQUENCE DATA;

EID: 33644790930     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201490     Document Type: Review

References (136)

1. Von Recklinghausen FD: Uber Hamochromatose. Berl Klin Wochenschr 1889; 26: 925.
2. Trousseau A: Glycosurie, diabète sucré. Clin Méd l'Hôtel Dieu de Paris 1865; 2: 663-698.
3. Sheldon JH: Haemochromatosis. London, UK: Oxford University Press, 1935.
4. Simon M, Alexandre JL, Fauchet R, Genetet B, Bourel M: The genetics of hemochomatosis. Progr Med Genet 1980; 4: 135-168.
5. Saddi R, Feingold J: IdAopathic haemochromatosis: an autosomal recessive disease. Clin Genet 1974; 5: 234-241.
6. Simon M, Bourel M, Fauchet R, Genetet B: Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 1976; 17: 332-334.
7. Simon M, Le Mignon L, Fauchet R et al: A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA association. Am J Hum Genet 1987; 41: 89-105.
8. Feder JN, Gnirke A, Thomas W et al: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
9. Zhou XY, Tomatsu S, Fleming RE et al: HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA 1998; 95: 2492-2497.
10. Jazwinska EC, Pyper WR, Burt MJ et al: Haplotype analysis in Australian hemochromatosis patients: Evidence for a predominant ancestral haplotype exclusively associated with hemochromatosis. Am J Hum Genet 1995; 56: 428-433.
11. Hanson EH, Imperatore G, Burke W: HFE gene and hereditary hemochromatosis: A HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154: 193-206.
12. Levy JE, Montross LK, Cohen DE, Fleming MD, Andrews NC: The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999; 94: 9-11.
13. Dupradeau F, Altenberg-Greulich B, Warin R, Fuentes V, Monti J, Rochette J: A 3-dimensional model building by homology of the HFE protein: molecular consequences and application to antibody development. Biochim Biophys Acta 2000; 1481: 213-221.
14. Camaschella C, Roetto A, Cali A et al: The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-15.
15. Njajou OT, Vaessen N, Joosse M et al: A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28: 213-214.
16. Roetto A, Papanikolaou G, Politou M et al: Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-22.
17. Papanikolaou G, Samuels ME, Ludwig EH et al: Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82.
18. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C: HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103: 2835-2840.
19. Merryweather-Clarke AT, Cadet E, Bomford A et al: Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12: 2241-2247.
20. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on haemochromatosis. J Hepatol 2000; 33: 485-504.
21. Camaschella C, Roetto A, De Gobbi M: Juvenile hemochromatosis. Semin Hematol 2002; 39: 242-248.
22. De Gobbi M, Roetto A, Piperno A et al: Natural history of juvenile haemochromatosis. Br J Haematol 2002; 117: 973-979.
23. Le Gac G, Mons F, Jacolot S, Scotet V, Ferec C, Frebourg T: Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 2004; 125: 674-678.
24. Pietrangelo A: The ferroportin disease. Blood Cells Mol Dis 2004; 32: 131-138.
25. Roetto A, Camaschella C: New insights into iron homeostasis through the study of non-HFE hereditary haemochromatosis. Best Pract Res Clin Haematol 2005; 18: 235-250.
26. Cazzola M: Genetic disorders of iron overload and the novel 'ferroportin disease'. Haematologica 2003; 88: 721-724.
27. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ: Geography of HFE C282Y and H63D mutations. Genet Test 2000; 4: 183-198.
28. Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ: Contribution of different HFE genotypes to iron overload disease: A pooled analysis. Genet Med 2000; 2: 271-277.
29. Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y: Phenotypic expression of HFE mutations: A French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999; 116: 372-377.
30. Lucotte G: Frequency analysis and allele map in favor of the celtic origin of the C282Y mutation of hemochromatosis. Blood Cells Mol Dis 2001; 27: 549-556.
31. Ryan E, O'keane C, Crowe J: Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 1998; 24: 428-432.
32. Jackson HA, Carter K, Darke C et al: HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001; 114: 474-484.
33. Distante S, Robson KJ, Graham-Campbell J, Arnaiz-Villena A, Brissot P, Worwood M: The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004; 115: 269-279.
34. Rochette J, Pointon JJ, Fisher CA et al: Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 1999; 64: 1056-1062.
35. Waalen J, Nordestgaard BG, Beutler E: The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 2005; 18: 203-220.
36. Datz C, Haas T, Rinner H, Sandhofer F, Patsch W, Paulweber B: Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: A protective role against iron deficiency? Clin Chem 1998; 44: 2429-2432.
37. Moalem S, Weinberg ED, Percy ME: Hemochromatosis and the enigma of misplaced iron: Implications for infectious disease and survival. Biometals 2004; 17: 135-139.
38. Le Gac G, Mura C, Ferec C: Complete scanning of the hereditary hemochromatosis gene (HFE) by use of denaturing HPLC. Clin Chem 2001; 47: 1633-1640.
39. Camaschella C, RoettG A, De Gobbi M: Genetic haemochromatosis: genes and mutations associated with iron loading. Best Pract Res Clin Haematol 2002; 15: 261-276.
40. Mura C, Raguenes O, Ferec C: HFE mutations analysis in 711 hemochromatosis probands: Evidence for S65C implication in mild form of hemochromatosis. Blood 1999; 93: 2502-2505.
41. Holmstrom P, Marmur J, Eggertsen G, Gafvels M, Stal P: Mild iron overload in patients carrying the HFE S65C gene mutation: A retrospective study in patients with suspected iron overload and healthy controls. Gut 2002; 51: 723-730.
42. Wallace DF, Walker AP, Pietrangelo A et al: Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. J Hepatol 2002; 36: 474-479.
43. Asberg A, Thorstensen K, Hveem K, Bjerve KS: Hereditary hemochromatosis: the clinical significance of the S65C mutation. Genet Test 2002; 6: 59-62.
44. Trombini P, Mauri V, Salvioni A, Corengia C, Arosio C, Piperno A: S65c frequency in Italian patients with hemochromatosis, porphyria cutanea tarda and chronic viral hepatitis with iron overload. Haematologica 2001; 86: 316-317.
45. Piperno A, Arosio C, Fossati L et al: Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 2000; 119: 441-445.
46. Rosmorduc O, Poupon R, Nion I et al: Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology 2000; 119: 1075-1086.
47. Le Gac G, Dupradeau FY, Mura C et al: Phenotypic expression of the C282Y/ Q283P compound heterozygosity in HFE and molecular modeling of the Q283P mutation effect. Blood Cells Mol Dis 2003; 30: 231-237.
48. Ka C, Le Gac G, Dupradeau F-Y, Rochette J, Ferec C: The Q283P amino acid change in HFE leads to structural and functional consequences similar to those described for the mutated 282Y HFE protein. Hum Genet 2005, (in press).
49. Drakesmith H, Sweetland E, Schimanski L et al: The hemochromatosis protein HFE inhibits iron export from macrophages. Proc Natl Acad Sci USA 2002; 99: 15602-15607.
50. Finch SC, Finch CA: Idiopathic hemochromatosis an iron storage disease: A. Iron metabolism in hemochromatosis. Medecine 1955; 34: 381-430.
51. Dadone MM, Kushner JP, Edwards CQ, Bishop DT, Skolnick MH: Hereditary hemochromatosis. Analysis of laboratory expression of the disease by genotype in 18 pedigrees. Am J Clin Pathol 1982; 78: 196-207.
52. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP: Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-1362.
53. Wiggers P, Dalhoj J, Kiaer H et al: Screening for haemochromatosis: prevalence among Danish blood donors. J Intern Med 1991; 230: 265-270.
54. Asberg A, Hveem K, Thorstensen K et al: Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001; 36: 1108-1115.
55. Adams PC, Reboussin DM, Barton JC et al: Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-1778.
56. Bomford A: Genetics of haemochromatosis. Lancet 2002; 360: 1673-1681.
57. Beutler E: The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003; 101: 3347-3350.
58. Worwood M: InheritGd iron loading: genetic testing in diagnosis and management. Blood Rev 2005; 19: 69-88.
59. Scotet V, Merour MC, Mercier AY et al: Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am J Epidemiol 2003; 158: 129-134.
60. Fletcher LM, Bridle KR, Crawford DH: Effect of alcohol on iron storage diseases of the liver. Best Pract Res Clin Gastroenterol 2003; 17: 663-677.
61. Levy JE, Montross LK, Andrews NC: Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000; 105: 1209-1216.
62. Nicolas G, Andrews NC, Kahn A, Vaulont S: Hepcidin, a candidate modifier of the hemochromatosis phenotype in mice. Blood 2004; 103: 2841-2843.
63. Bensaid M, Fruchon S, Mazeres C, Bahram S, Roth MP, Coppin H: Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology 2004; 126: 1400-1408.
64. Le Gac G, Scotet V, Ka C et al: The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004; 13: 1913-1918.
65. Livesey KJ, Wimhurst VL, Carter K et al: The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. J Med Genet 2004; 41: 6-10.
66. Roetto A, Totaro A, Cazzola M et al: Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999; 64: 1388-1393.
67. Lanzara C, Roetto A, Daraio F et al: Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 2004; 103: 4317-4321.
68. Lee PL, Beutler E, Rao SV, Barton JC: Genetic abnormalities and juvenile hemochromatosis: Mutations of the HJV gene encoding hemojuvelin. Blood 2004; 103: 4669-4671.
69. Gehrke SG, Pietrangelo A, Kascak M et al: HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet 2005; 67: 425-428.
70. Huang FW, Rubio-Aliaga I, Kushner JP, Andrews NC, Fleming MD: Identification of a novel mutation (C321X) in HJV. Blood 2004; 104: 2176-2177.
71. Wallace DF, Dixon JL, Ramm GA, Anderson GJ, Powell LW, Subramaniam N: Hemojuvelin (HJV)-associated hemochromatosis: Analysis of HJV and HFE mutations and iron overload in three families. Haematologica 2005; 90: 254-255.
72. Janosi A, Andrikovics H, Vas K et al: Homozygosity for a novel nonsense mutation (G66X) of the HJV gene causes severe juvenile hemochromatosis with fatal cardiomyopathy. Blood 2005; 105: 432.
73. Majore S, Binni F, Pennese A, De Santis A, Crisi A, Grammatico P: HAMP gene mutation c.208T>C (p.C70R) identified in an Italian patient with severe hereditary hemochromatosis. Hum Mutat 2004; 23: 400.
74. Roetto A, Daraio F, Porporato P et al: Screening hepcidin for mutations in juvenile hemochromatosis: Identification of a new mutation (C70R). Blood 2004; 103: 2407-2409.
75. Delatycki MB, Allen KJ, Gow P et al: A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. Clin Genet 2004; 65: 378-383.
76. Matthes T, Aguilar-Martinez P, Pizzi-Bosman L et al: Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5′-UTR of the HAMP gene. Blood 2004; 104: 2181-2183.
77. Krause A, Neitz S, Magert HJ et al: LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-150.
78. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
79. Pigeon C, Ilyin G, Courselaud B et al: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819.
80. Nicolas G, Bennoun M, Devaux I et al: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780-8785.
81. Nicolas G, Bennoun M, Porteu A et al: Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596-4601.
82. Ganz T: Hepcidin - a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005; 18: 171-182.
83. Roy CN, Andrews NCT Anemia of inflammation: the hepcidin link. Curr Opin Hematol 2005; 12: 107-111.
84. Fleming RE, Bacon BR: Orchestration of iron homeostasis. N Engl J Med 2005; 352: 1741-1744.
85. Leong WI, Lonnerdal B: Hepcidin, the recently identified peptide that appears to regulate iron absorption. J Nutr 2004; 134: 1-4.
86. Nemeth E, Tuttle MS, Powelson J et al: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
87. Bridle KR, Frazer DM, Wilkins SJ et al: Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361: 669-673.
88. Ahmad KA, Ahmann JR, Migas MC et al: Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells Mol Dis 2002; 29: 361-366.
89. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C: Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005; 105: 1803-1806.
90. Kawabata H, Fleming RE, Gui D et al: Expression of hepcidin is down-regulated in TFR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2005; 105: 376-381.
91. Fleming RE, Ahmann JR, Migas MC et al: Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci USA 2002; 99: 10653-10658.
92. Hattori A, Wakusawa S, Hayashi H et al: AVAQ 594-597 deletion of the TFR2 gene in a Japanese family with hemochromatosis. Hepatol Res 2003; 26: 154-156.
93. Roetto A, Totaro A, Piperno A et al: New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 97: 2555-2560.
94. Girelli D, Bozzini C, Roetto A et al: Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002; 122: 1295-1302.
95. Mattman A, Huntsman D, Lockitch G et al: Transferrin receptor 2 (TFR2) and HFE mutational analysis in non-C282Y iron overload: Identification of a novel TFR2 mutation. Blood 2002; 100: 1075-1077.
96. Pietrangelo A, Caleffi A, Henrion J et al: Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128: 470-479.
97. Koyama C, Wakusawa S, Hayashi H et al: Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica 2005; 90: 302-307.
98. Kawabata H, Yang R, Hirama T et al: Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826-20832.
99. Fleming RE, Migas CC, Holden CC et al: Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci USA 2000; 97: 2214-2219.
100. Zhang AS, Xiong S, Tsukamoto H, Enns CA: Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood 2004; 103: 1509-1514.
101. Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW, Koeffler HP: Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. J Biol Chem 2000; 275: 16618-16625.
102. Johnson MB, Enns CA: Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 2004; 104: 4287-4293.
103. Robb A, Wessling-Resnick M: Regulation of transferrin receptor 2 protein levels by transferrin. Blood 2004; 104: 4294-4299.
104. Eason RJ, Adams PC, Aston CE, Searle J: Familial iron overload with possible autosomal dominant inheritance. Aust NZ J Med 1990; 20: 226-230.
105. Pietrangelo A, Montosi G, Totaro A et al: Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341: 725-732.
106. Montosi G, Donovan A, Totaro A et al: Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619-623.
107. Arden KE, Wallace DF, Dixon JL et al: A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient. Gut 2003; 52: 1215-1217.
108. Cazzola M, Cremonesi L, Papaioannou M et al: Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol 2002; 119: 539-546.
109. Devalia V, Carter K, Walker AP et al: Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002; 100: 695-697.
110. Wallace DF, Pedersen P, Dixon JL et al: Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100: 692-694.
111. Roetto A, Merryweather-Clarke AT, Daraio F et al: A valine deletion of ferroportin 1: A common mutation in hemochromastosis type 4. Blood 2002; 100: 733-734.
112. Barton JC, Acton RT, Rivers CA et al: Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis 2003; 31: 310-319.
113. Gordeuk VR, Caleffi A, Corradini E et al: Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003; 31: 299-304.
114. Beutler E, Barton JC, Felitti VJ et al: Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31: 305-309.
115. Schimanski LM, Drakesmith H, Merryweather-Clarke AT et al: In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 2005; 105: 4096-4102.
116. Robson KJ, Merryweather-Clarke AT, Cadet E et al: Recent advances in understanding haemochromatosis: A transition state. J Med Genet 2004; 41: 721-730.
117. Donovan A, Brownlie A, Zhou Y et al: Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-781.
118. McKie AT, Marciani P, Rolfs A et al: A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5: 299-309.
119. Abboud S, Haile DJ: A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19906-19912.
120. Fleming RE, Sly WS: Ferroportin mutation in autosomal dominant hemochromatosis: Loss of function, gain in understanding. J Clin Invest 2001; 108: 521-522.
121. Drakesmith H, Schimanski LM, Ormerod E et al: Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005; 106: 1092-1097.
122. Knutson M, Wessling-Resnick M: Iron metabolism in the reticuloendothelial system. Crit Rev Biochem Mol Biol 2003; 38: 61-88.
123. Papanikolaou G, Tzilianos M, Christakis JI et al: Hepcidin in iron overload disorders. Blood 2005; 105: 4103-4105.
124. Rivard SR, Lanzara C, Grimard D et al: Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica 2003; 88: 824-826.
125. Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E: Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005; 34: 157-161.
126. Wallace DF, Clark RM, Harley HA, Subramaniam VN: Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. J Hepatol 2004; 40: 710-713.
127. Njajou OT, de Jong G, Berghuis B et al: Dominant hemochromatosis due to N144H mutation of SLC11A3: Clinical and biological characteristics. Blood Cells Mol Dis 2002; 29: 439-443.
128. Njajou OT, Vaessen N, Oostra B, Heutink P, van Duijn CM: The hemochromatosis N144H mutation of SLC11A3 gene in patients with type 2 diabetes. Mol Genet Metab 2002; 75: 290-291.
129. Ming JE, Muenke M: Multiple hits during early embryonic development: digenic diseases and holoprosencephaly. Am J Hum Genet 2002; 71: 1017-1032.
130. Townsend A, Drakesmith H: Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet 2002; 359: 786-790.
131. Mura C, Le Gac G, Jacolot S, Ferec C: Transcriptional regulation of the human HFE gene indicates high liver expression and erythropoiesis coregulation. FASEB J 2004; 18: 1922-1924.
132. Scotet V, Le Gac G, Merour MC et al: Impact of HFE testing on clinical presentation of hereditary hemochromatosis: New epidemiological data. BMC Med Genet 2005; 6: 24.
133. Pietrangelo A: Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004; 350: 2383-2397.
134. Biasiotto G, Belloli S, Ruggeri G et al: Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003; 49: 1981-1988.
135. McCullen MA, Crawford DH, Hickman PE: Screening for hemochromatosis. Clin Chim Acta 2002; 315: 169-186.
136. Krawczak M, Cooper DN, Schmidtke J: Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 2001; 69: 361-370.